Literature DB >> 1621073

The McLean First-Episode Psychosis Project: six-month recovery and recurrence outcome.

M Tohen1, A L Stoll, S M Strakowski, G L Faedda, P V Mayer, D C Goodwin, M L Kolbrener, A M Madigan.   

Abstract

The McLean First-Episode Psychosis project began in 1989. The authors describe the study design, diagnostic distribution, and recovery and relapse data on the first 102 recruited subjects. Fifty-nine percent of the subjects had a diagnosis of bipolar disorder, 15 percent psychotic depression, 10 percent schizophrenic spectrum, 9 percent delusional disorder, and 8 percent other psychotic disorders. By 6 months, 80 percent recovered syndromically but only 55 percent recovered functionally, and only 50 percent recovered both functionally and syndromically. Non-white and male patients were more likely to have a recurrence. Men were less likely and bipolar patients were more likely to recover functionally. Patients with nonaffective psychosis had longer hospitalizations and lower rates of functional recovery 6 months after discharge.

Entities:  

Mesh:

Year:  1992        PMID: 1621073     DOI: 10.1093/schbul/18.2.273

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  13 in total

1.  Substance use disorders in individuals with body dysmorphic disorder.

Authors:  Jon E Grant; William Menard; Maria E Pagano; Christina Fay; Katharine A Phillips
Journal:  J Clin Psychiatry       Date:  2005-03       Impact factor: 4.384

Review 2.  Bipolar disorder and health-related quality of life : review of burden of disease and clinical trials.

Authors:  Dennis A Revicki; Louis S Matza; Emuella Flood; Andrew Lloyd
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 3.  Schizophrenia.

Authors:  M Cannon; P Jones
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-06       Impact factor: 10.154

4.  First-episode schizophrenic psychosis differs from first-episode affective psychosis and controls in P300 amplitude over left temporal lobe.

Authors:  D F Salisbury; M E Shenton; A R Sherwood; I A Fischer; D A Yurgelun-Todd; M Tohen; R W McCarley
Journal:  Arch Gen Psychiatry       Date:  1998-02

5.  MRI study of cavum septi pellucidi in schizophrenia, affective disorder, and schizotypal personality disorder.

Authors:  J S Kwon; M E Shenton; Y Hirayasu; D F Salisbury; I A Fischer; C C Dickey; D Yurgelun-Todd; M Tohen; R Kikinis; F A Jolesz; R W McCarley
Journal:  Am J Psychiatry       Date:  1998-04       Impact factor: 18.112

6.  Substance use disorders in an obsessive compulsive disorder clinical sample.

Authors:  Maria C Mancebo; Jon E Grant; Anthony Pinto; Jane L Eisen; Steven A Rasmussen
Journal:  J Anxiety Disord       Date:  2008-09-06

7.  The functional impact of subsyndromal depressive symptoms in bipolar disorder: data from STEP-BD.

Authors:  Lauren B Marangell; Ellen B Dennehy; Sachiko Miyahara; Stephen R Wisniewski; Mark S Bauer; Mark Hyman Rapaport; Michael H Allen
Journal:  J Affect Disord       Date:  2008-08-15       Impact factor: 4.839

8.  The Effect of Paternal Age on Relapse in First-Episode Schizophrenia.

Authors:  Christy L M Hui; Cindy P Y Chiu; Yuet-Keung Li; Chi-Wing Law; Wing-Chung Chang; Sherry K W Chan; Edwin H M Lee; Pak Sham; Eric Y H Chen
Journal:  Can J Psychiatry       Date:  2015-08       Impact factor: 4.356

Review 9.  Pharmacological management of first-episode schizophrenia and related nonaffective psychoses.

Authors:  Daniel W Bradford; Diana O Perkins; Jeffrey A Lieberman
Journal:  Drugs       Date:  2003       Impact factor: 9.546

10.  Treatment and outcomes of an Australian cohort of outpatients with bipolar I or schizoaffective disorder over twenty-four months: implications for clinical practice.

Authors:  Jayashri Kulkarni; Sacha Filia; Lesley Berk; Kate Filia; Seetal Dodd; Anthony de Castella; Alan J M Brnabic; Amanda J Lowry; Katarina Kelin; William Montgomery; Paul B Fitzgerald; Michael Berk
Journal:  BMC Psychiatry       Date:  2012-12-17       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.